Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denikitug alone or in combination for advanced MSS colorectal cancer
2025-523984-39-00Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of denikitug in colorectal cancer (CRC) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Objective response rate. Started Jun 2026; status: completed.
02
Drugs
denikitug
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2025-523984-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523984-39-00.